Targeted therapy and immunotherapy for malignant mesothelioma
10.16352/j.issn.1001-6325.2024.10.1342
- VernacularTitle:恶性间皮瘤的靶向与免疫治疗
- Author:
Junhao YANG
1
;
Lin ZHAO
Author Information
1. 中国医学科学院 北京协和医学院 北京协和医院 肿瘤内科,北京 100730
- Keywords:
mesothelioma;
targeted therapy;
immunotherapy;
oncolytic virus;
CAR-T
- From:
Basic & Clinical Medicine
2024;44(10):1342-1349
- CountryChina
- Language:Chinese
-
Abstract:
Malignant mesothelioma(MMe)is a malignant tumor originating from mesothelial tissues,occurring mostly in locations like pleura,pericardium and peritoneum.The extensive research on its treatment has been car-ried on as tackling to the challenge of poor prognosis of the disease.Conventional treatment modalities including sur-gery,chemotherapy and radiotherapy all exhibit limited efficacy,resulting in persistently low survival rates.Hence,exploring novel therapeutic approaches is paramount for improving the prognosis of mesothelioma patients.Targeted therapy and immunotherapy,as emerging cancer treatment modalities,exert their effects by targeting specific mo-lecular markers on tumor cells or immune cells,thus inhibiting tumor growth and metastasis,thereby offering new hope for mesothelioma treatment.This article provides a comprehensive review of recent research progress in targeted therapy and immunotherapy for mesothelioma.
